Pharma Industry

A World Health Organization (WHO) panel has given the green light to two new drugs to treat COVID-19. US-based Eli Lilly’s baricitinib (Olumiant), a Janus kinase inhibitor, and GlaxoSmithKline and Vir Biotechnology’s sotrovimab, a monoclonal antibody, were recommended in new WHO guidelines, published in the British Medical Journal.  Baricitinib, administered with corticosteroids, was strongly recommended as
0 Comments
The details are slim, but Novo Nordisk seems to be in the clear after shareholders took the diabetes juggernaut to court nearly three years ago over the company’s public communications about its struggling insulin business. Novo Nordisk said Friday that it’s settled a Danish securities lawsuit from the summer of 2019. The agreement “contains no
0 Comments
Look out, Sanofi and Regeneron: Pfizer is on the scene in atopic dermatitis with another blockbuster-to-be.  Friday, the FDA approved the New York drugmaker’s oral daily JAK1 inhibitor Cibinqo to treat adults with moderate to severe atopic dermatitis who have not been able to get their disease under control with other medicines including biologics and
0 Comments
After a false start in Europe, bluebird bio is determined to give its trio of gene therapies a better shot in the U.S.  Bluebird is readying the commercial nest ahead of a May decision on its beta thalassemia gene therapy beti-cel, also known as Zynteglo. Those preparations will be “crucial” to unlocking the blockbuster potential
0 Comments
Order up. Shortly after topping off supplies of COVID-19 drugs from Pfizer and GlaxoSmithKline, the U.S. has asked for a second helping of AstraZeneca’s antibody combo. The government has purchased an additional 500,000 doses of AZ’s long-acting antibody cocktail Evusheld, or tixagevimab plus cilgavimab. That comes on top of 700,000 doses the U.S. already ordered,
0 Comments
Ahead of its state-of-the-company address at the J.P. Morgan Healthcare Conference, AbbVie took the unusual step of reconfirming its guidance for its blockbusters-in-waiting Rinvoq and Skyrizi, saying it expects the duo’s sales to reach a combined $15 billion in 2025. Why update an estimate that hasn’t changed? While AbbVie expects the two to produce the
0 Comments
As the COVID-19 pandemic continues to impact the healthcare landscape, and the digital transformation of the life sciences industry gathers pace, what can we expect to see in 2022? In this webinar, senior members from Healthware Group discuss the key trends and developments set to shape the industry and present their predictions for the year
0 Comments
When Bristol Myers Squibb unveiled its massive Celgene buyout ahead of 2019’s J.P. Morgan Healthcare Conference, executives knew Celgene’s blockbuster blood cancer drug Revlimid would face generics sometime in the years that followed. In 2022, the key patent cliff is here. Fear not, BMS CEO Giovanni Caforio assured investors on Monday. Opening the conference’s 2022
0 Comments
COVID-19 vaccine developers have enjoyed a windfall and so have their chief executives. Now, a group of investors are asking the companies to improve vaccine equity by heaping pressure at the C-suite level. Pay packages for CEOs at COVID vaccine makers Pfizer, Johnson & Johnson, Moderna and AstraZeneca should be tied to making their shots
0 Comments